R. Kataria

发表

Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.

S. DiBiase, A. Hussain, Y. Kwok, 2011, International journal of radiation oncology, biology, physics.

Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.

M. Tan, W. Regine, M. Mohiuddin, 2007, International journal of radiation oncology, biology, physics.

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

M. Milowsky, S. Srinivas, A. Balar, 2021, Journal of Clinical Oncology.

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Pankaj Chopra, Zhiyong Guo, P. Chopra, 2005, Journal of medicinal chemistry.

798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer

T. Powles, M. Galsky, Sumati Gupta, 2020 .

Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.

J. Witjes, M. Galsky, H. Nishiyama, 2021, Future oncology.

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model

V. Njar, A. Brodie, B. Long, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).

T. Powles, M. S. van der Heijden, C. Derleth, 2022, Journal of Clinical Oncology.

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

M. Galsky, H. Nishiyama, J. Bedke, 2021 .

Cancer caregiving and subjective stress: a multi‐site, multi‐dimensional analysis

J. Gaugler, N. Hanna, C. Given, 2005, Psycho-oncology.

Work, gender, and stress in family cancer caregiving

J. Gaugler, W. Regine, R. Kataria, 2008, Supportive Care in Cancer.

The Proliferation of Primary Cancer Caregiving Stress to Secondary Stress

J. Gaugler, W. Regine, C. Given, 2008, Cancer nursing.

Family Cancer Caregiving and Negative Outcomes: The Direct and Mediational Effects of Psychosocial Resources

J. Gaugler, W. Regine, C. Given, 2009, Journal of family nursing.

Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.

H. Nishiyama, G. Steinberg, A. Siefker-Radtke, 2020 .

Phase II study of combined external beam radiation therapy (EBRT), brachytherapy (PB), total androgen suppression (TAS), and adjuvant docetaxel (AD) in poor-risk, localized prostate cancer (PCa).

S. DiBiase, A. Hussain, N. Dawson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study

A. Balar, P. Grivas, M. S. van der Heijden, 2024, BMC cancer.

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

T. Flaig, S. Bracarda, A. Carret, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

A. Peer, R. Kataria, R. Leibowitz, 2024, BMC cancer.